Bispecific Antibody Targets TIM-3 and CD39 for Cancer

ChangeBridge: Patent Apps - Peptides (C07K)

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085127A1) for a bispecific antibody designed to target both TIM-3 and CD39 antigens. This antibody aims to enhance immune activity against cancer cells and is intended for cancer treatment.

View original document View source feed page

What changed

This document is a publication of a patent application from the USPTO detailing a novel bispecific antibody. The antibody is engineered to bind to both the TIM-3 and CD39 antigens, which are involved in immune checkpoint inhibition. The described antibody or antibody derivative is intended to enhance the immune system's activity against cancer cells and is proposed for use in cancer therapy.

This patent application does not impose immediate regulatory obligations on pharmaceutical companies or drug manufacturers. However, it signifies potential future developments in cancer therapeutics. Companies involved in oncology drug development may wish to monitor the progress of this patent and similar research for competitive intelligence and potential licensing or collaboration opportunities.

Source document (simplified)

← USPTO Patent Applications

BISPECIFIC ANTIBODY TO HUMAN TIM-3 AND HUMAN CD39, AND USE THEREOF

Application US20260085127A1 Kind: A1 Mar 26, 2026

Inventors

Norihiro NAKAMURA, Kanto NAKAJIMA, Yuji MISHIMA, Noriko MATSUMOTO

Abstract

An antibody or antibody derivative having a higher immune checkpoint inhibitory effect. The antibody or antibody derivative is capable of enhancing immune activity against cancer cells, and can be used to treat cancer. The antibody is a heterodimeric antibody or antibody derivative capable of binding to both the TIM-3 and CD39 antigens. The heterodimeric antibody or antibody derivative is capable of enhancing immune activity against cancer cells.